Accelerating Growth At Half Year For Sandoz

14 July 1996

Sales in the first six months of 1996 at Sandoz amounted to 7.9 billion Swiss francs ($6.2 billion). Excluding divestitures, the group said this represented an increase of 8% in local currencies and 7% in Swiss franc terms.

The acceleration in the speed of growth was attributed to an "outstanding performance" by the pharmaceuticals division. Prescription product sales advanced 12%, due to sustained expansion of the biggest-selling drugs, the company said.

The breakdown of turnover for the first six months of the year (in million Swiss francs) is as follows:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight